Novelix Pharmaceuticals Announces Shares Allotment to Promoter Group Members
Novelix Pharmaceuticals Ltd has announced that shares were allotted to members of the promoter group following the conversion of warrants issued through a Preferential Allotment. Neha Gattu was among those allocated 100,000 Equity Shares on July 9, 2026.The allotment transaction involved I. Gattu Gnana Prakash, Arati Gattu, and Neha Gattu, all members of the promoter group, in connection with the conversion of warrants into equity shares.
Acquisition Details
Prior to the acquisition, the holdings among the three promoters were as follows:| Promoter Name | Shares Carried Voting Rights (A) | Total Diluted Capital % |
|---|---|---|
| I. Gattu Gnana Prakash | 100,000 | 1.67% |
| Arati Gattu | 0 | 0.42% |
| Neha Gattu | 0 | 0.42% |
The acquisition involved the allotment of 100,000 shares to Neha Gattu. Following this event, the holdings among the promoter group members were recorded as:
| Promoter Name | Shares Carrying Voting Rights (A) |
|---|---|
| I. Gattu Gnana Prakash | 4,00,000 |
| Arati Gattu | 0 |
| Neha Gattu | 100,000 |
The mode of acquisition was specified as the conversion of warrants into Equity Shares issued on a Preferential Allotment basis.
Capital Structure Post Transaction
Details regarding the company's capital structure before and after the transaction are as follows:| Financial Metric | Before Acquisition | After Acquisition |
|---|---|---|
| Equity Share Capital (Face Value) | Rs. 238,950,000/- (of Rs. 10/- each) | Rs. 28,47,00,000/- (of Rs. 10/- each) |
| Total Diluted Share/Voting Capital | Rs. 27,27,00,000/- | Rs. 28,47,00,000/- |
Stock Price Movement
As of 13:01, Novelix Pharmaceuticals Ltd.'s shares are dipping by 4.47% to ₹63.53. The stock has traded within a significant range today, testing an intraday high of ₹67.50 before finding support near the low of ₹63.20.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.